Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R.

Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.

PMID:
28028022
2.

Genetic Advances in the Understanding of Microtia.

Gendron C, Schwentker A, van Aalst JA.

J Pediatr Genet. 2016 Dec;5(4):189-197. Epub 2016 Sep 23. Review.

PMID:
27895971
3.

In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon.

Murai T, Kawashita N, Tian YS, Takagi T.

Springerplus. 2016 Jul 19;5(1):1122. doi: 10.1186/s40064-016-2761-9. eCollection 2016.

4.

Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6.

Min Y, Wi SM, Kang JA, Yang T, Park CS, Park SG, Chung S, Shim JH, Chun E, Lee KY.

Cell Death Dis. 2016 Jul 28;7(7):e2313. doi: 10.1038/cddis.2016.226.

5.

Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Yamazaki H, Suemizu H, Mitsui M, Shimizu M, Guengerich FP.

Chem Res Toxicol. 2016 Dec 19;29(12):1903-1911. Epub 2016 Jul 5.

6.

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402.

PMID:
27291302
7.

The status of diabetic embryopathy.

Eriksson UJ, Wentzel P.

Ups J Med Sci. 2016 May;121(2):96-112. doi: 10.3109/03009734.2016.1165317. Epub 2016 Apr 27.

8.

Kupffer Cell Metabolism and Function.

Nguyen-Lefebvre AT, Horuzsko A.

J Enzymol Metab. 2015;1(1). pii: 101. Epub 2015 Aug 14.

9.

Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Kazuki Y, Akita M, Kobayashi K, Osaki M, Satoh D, Ohta R, Abe S, Takehara S, Kazuki K, Yamazaki H, Kamataki T, Oshimura M.

Sci Rep. 2016 Feb 23;6:21419. doi: 10.1038/srep21419.

10.

Maternal diabetes triggers DNA damage and DNA damage response in neurulation stage embryos through oxidative stress.

Dong D, Yu J, Wu Y, Fu N, Villela NA, Yang P.

Biochem Biophys Res Commun. 2015 Nov 13;467(2):407-12. doi: 10.1016/j.bbrc.2015.09.137. Epub 2015 Sep 30.

11.

Thalidomide-induced teratogenesis: history and mechanisms.

Vargesson N.

Birth Defects Res C Embryo Today. 2015 Jun;105(2):140-56. doi: 10.1002/bdrc.21096. Epub 2015 Jun 4. Review.

12.

Air toxics and birth defects: a Bayesian hierarchical approach to evaluate multiple pollutants and spina bifida.

Swartz MD, Cai Y, Chan W, Symanski E, Mitchell LE, Danysh HE, Langlois PH, Lupo PJ.

Environ Health. 2015 Feb 9;14:16. doi: 10.1186/1476-069X-14-16.

13.

Combination therapy with A1 receptor agonist and vitamin C improved working memory in a mouse model of global ischemia-reperfusion.

Zamani M, Katebi M, Mehdizadeh M, Kafami L, Soleimani M.

Basic Clin Neurosci. 2013 Spring;4(2):111-6.

14.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK.

Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.

15.

LETM1 haploinsufficiency causes mitochondrial defects in cells from humans with Wolf-Hirschhorn syndrome: implications for dissecting the underlying pathomechanisms in this condition.

Hart L, Rauch A, Carr AM, Vermeesch JR, O'Driscoll M.

Dis Model Mech. 2014 May;7(5):535-45. doi: 10.1242/dmm.014464. Epub 2014 Mar 13.

16.

Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Murayama N, van Beuningen R, Suemizu H, Guguen-Guillouzo C, Shibata N, Yajima K, Utoh M, Shimizu M, Chesné C, Nakamura M, Guengerich FP, Houtman R, Yamazaki H.

Chem Res Toxicol. 2014 Feb 17;27(2):304-8. doi: 10.1021/tx4004374. Epub 2014 Feb 5.

17.

Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Chowdhury G, Shibata N, Yamazaki H, Guengerich FP.

Chem Res Toxicol. 2014 Jan 21;27(1):147-56. doi: 10.1021/tx4004215. Epub 2013 Dec 24.

18.

The clinical significance of cereblon expression in multiple myeloma.

Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK.

Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.

19.

Thalidomide-a notorious sedative to a wonder anticancer drug.

Zhou S, Wang F, Hsieh TC, Wu JM, Wu E.

Curr Med Chem. 2013;20(33):4102-8. Review.

20.

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.

Zhu YX, Kortuem KM, Stewart AK.

Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. Review.

Supplemental Content

Support Center